Immunitybio

Immunitybio Net Change in Cash

The Net Change in Cash of Immunitybio (IBRX) as of Oct 20, 2026 is -54.48 M USD. In the previous year, Net Change in Cash was -121.88 M USD — a change of -55.30% (higher).

Net Change in Cash

-54.48 MUSD

YoY

-55.30%

Last updated:

Net Change in Cash of Immunitybio is 2025 -54.48 M USD. Net Change in Cash of Immunitybio was 2024 -121.88 M USD. It decreases by -55.30% higher compared to the previous year.

The Immunitybio Net Change in Cash history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Change in Cash
Date
Net Change in Cash
Jan 1, 2018
-7.05 M USD
Jan 1, 2019
-19.30 M USD
Jan 1, 2020
-40.89 M USD
Jan 1, 2021
146.19 M USD
Jan 1, 2022
-76.32 M USD
Jan 1, 2023
160.82 M USD
Jan 1, 2024
-121.88 M USD
Jan 1, 2025
-54.48 M USD
The Immunitybio Net Change in Cash history
YEARNet Change in CashYoY
-54.48 MUSD-55.30%
-121.88 MUSD-175.78%
160.82 MUSD-310.73%
-76.32 MUSD-152.20%
146.19 MUSD-457.55%
-40.89 MUSD+111.86%
-19.30 MUSD+173.71%
-7.05 MUSD-144.66%
15.79 MUSD-109.41%
-167.83 MUSD-243.68%
116.80 MUSD+98.80%
58.75 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Immunitybio Stock analysis

What does Immunitybio do? Translate this as near as possible to English. ImmunityBio Inc is a biotechnology company specializing in innovative methods to combat cancer and other serious diseases. The company was founded in 2015 by esteemed biotech entrepreneur and scientist, Dr. Patrick Soon-Shiong. The idea behind ImmunityBio was to create a company focused on developing advanced immunotherapies that involve the human immune system in the fight against cancer. The business model is based on several business units, including research and development, diagnostics, and therapeutics. In recent years, the company has expanded through a series of significant acquisitions and mergers, including CytRx Corporation, NantWorks LLC, and NantKwest Inc. Together, these mergers have expanded and united the resources and expertise of ImmunityBio to achieve new advancements in oncology. ImmunityBio has also developed a variety of products focused on strengthening the immune system, including its leading drug, INT-001, intended for the treatment of lung, pancreatic, breast, stomach, and colorectal cancer. The company has also developed diagnostic products, such as the ImmuneMap™ test, which analyzes the patient's immune profile and can contribute to better combinations of existing immunotherapies. Another business unit is the service department, which focuses on providing services related to precision medicine. ImmunityBio offers a wide range of personalized drugs and services to help provide patients with better and more effective treatment. The company also has an extensive pipeline of immunotherapies for various indications, including several clinical trials for the treatment of lung cancer, pancreatic cancer, and breast cancer. The portfolio includes both single agents and combination therapies, which the company will introduce after a rigorous phase 1 study. Overall, ImmunityBio has an ambitious goal of being a leading player in the innovation of immunotherapies. Through a multidisciplinary approach to the discovery and development of new treatments, ImmunityBio is working to defeat cancer by strengthening the immune system and improving the quality of life for patients worldwide. Immunitybio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Immunitybio stock

Net Change in Cash of Immunitybio is -54.48 M USD in 2025.

Net Change in Cash of Immunitybio changed from -121.88 M USD to -54.48 M USD, representing a -55.30% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Change in Cash Immunitybio since 2006 – with annual values, charts, and detailed analysis.

Net change in cash is the total change in cash and equivalents during the period, combining operating, investing, and financing cash flows.

Net Change in Cash's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Change in Cash's Immunitybio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Immunitybio

All Key Metrics — Immunitybio